BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31678930)

  • 1. Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion.
    Méant A; Gao B; Lavoie G; Nourreddine S; Jung F; Aubert L; Tcherkezian J; Gingras AC; Roux PP
    Mol Cell Proteomics; 2020 Jan; 19(1):50-64. PubMed ID: 31678930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
    Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
    Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
    Romeo Y; Moreau J; Zindy PJ; Saba-El-Leil M; Lavoie G; Dandachi F; Baptissart M; Borden KLB; Meloche S; Roux PP
    Oncogene; 2013 Jun; 32(24):2917-2926. PubMed ID: 22797077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3.
    Galan JA; Geraghty KM; Lavoie G; Kanshin E; Tcherkezian J; Calabrese V; Jeschke GR; Turk BE; Ballif BA; Blenis J; Thibault P; Roux PP
    Proc Natl Acad Sci U S A; 2014 Jul; 111(29):E2918-27. PubMed ID: 25002506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation.
    Li P; Goto H; Kasahara K; Matsuyama M; Wang Z; Yatabe Y; Kiyono T; Inagaki M
    Mol Biol Cell; 2012 Apr; 23(8):1582-92. PubMed ID: 22357623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
    Kosnopfel C; Wendlinger S; Niessner H; Siewert J; Sinnberg T; Hofmann A; Wohlfarth J; Schrama D; Berthold M; Siedel C; Sauer B; Jayanthan A; Lenz G; Dunn SE; Schilling B; Schittek B
    J Exp Clin Cancer Res; 2023 Jul; 42(1):175. PubMed ID: 37464364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad.
    Eisenmann KM; VanBrocklin MW; Staffend NA; Kitchen SM; Koo HM
    Cancer Res; 2003 Dec; 63(23):8330-7. PubMed ID: 14678993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling.
    Abe Y; Yoon SO; Kubota K; Mendoza MC; Gygi SP; Blenis J
    J Biol Chem; 2009 May; 284(22):14939-48. PubMed ID: 19332537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.
    Roux PP; Richards SA; Blenis J
    Mol Cell Biol; 2003 Jul; 23(14):4796-804. PubMed ID: 12832467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)-ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration.
    Yang S; Ji M; Zhang L; Chen Y; Wennmann DO; Kremerskothen J; Dong J
    Cell Signal; 2014 Feb; 26(2):343-51. PubMed ID: 24269383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex formation between S100B protein and the p90 ribosomal S6 kinase (RSK) in malignant melanoma is calcium-dependent and inhibits extracellular signal-regulated kinase (ERK)-mediated phosphorylation of RSK.
    Hartman KG; Vitolo MI; Pierce AD; Fox JM; Shapiro P; Martin SS; Wilder PT; Weber DJ
    J Biol Chem; 2014 May; 289(18):12886-95. PubMed ID: 24627490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
    Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
    Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.
    Aronchik I; Appleton BA; Basham SE; Crawford K; Del Rosario M; Doyle LV; Estacio WF; Lan J; Lindvall MK; Luu CA; Ornelas E; Venetsanakos E; Shafer CM; Jefferson AB
    Mol Cancer Res; 2014 May; 12(5):803-12. PubMed ID: 24554780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma.
    Houles T; Gravel SP; Lavoie G; Shin S; Savall M; Méant A; Grondin B; Gaboury L; Yoon SO; St-Pierre J; Roux PP
    Cancer Res; 2018 May; 78(9):2191-2204. PubMed ID: 29440170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RSK factors of activating the Ras/MAPK signaling cascade.
    Carriere A; Ray H; Blenis J; Roux PP
    Front Biosci; 2008 May; 13():4258-75. PubMed ID: 18508509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling.
    Lopez J; Bonsor DA; Sale MJ; Urisman A; Mehalko JL; Cabanski-Dunning M; Castel P; Simanshu DK; McCormick F
    J Biol Chem; 2023 Jun; 299(6):104789. PubMed ID: 37149146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
    Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
    Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
    Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
    Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gab2 phosphorylation by RSK inhibits Shp2 recruitment and cell motility.
    Zhang X; Lavoie G; Fort L; Huttlin EL; Tcherkezian J; Galan JA; Gu H; Gygi SP; Carreno S; Roux PP
    Mol Cell Biol; 2013 Apr; 33(8):1657-70. PubMed ID: 23401857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.